The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression

Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. 7-Methylguanosine (m7G), one of the most prevalent RNA modifications, has been reported to play an important role in ccRCC progression; however, the specific regulators of m7G modification that are involv...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi Liu, Yanji Zhan, Jiao Liu, Zhengze Shen, Yudong Hu, Ling Zhong, Yuan Yu, Bin Tang, Jing Guo
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Translational Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523324003280
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850169684352040960
author Yi Liu
Yanji Zhan
Jiao Liu
Zhengze Shen
Yudong Hu
Ling Zhong
Yuan Yu
Bin Tang
Jing Guo
author_facet Yi Liu
Yanji Zhan
Jiao Liu
Zhengze Shen
Yudong Hu
Ling Zhong
Yuan Yu
Bin Tang
Jing Guo
author_sort Yi Liu
collection DOAJ
description Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. 7-Methylguanosine (m7G), one of the most prevalent RNA modifications, has been reported to play an important role in ccRCC progression; however, the specific regulators of m7G modification that are involved in this function remain unclear. This study aimed to explore the correlation between regulators of m7G methylation and ccRCC progression using unsupervised machine learning methods.Methods: Transcriptome and clinical data of ccRCC were retrieved from The Cancer Genome Atlas (TCGA) database to identify differentially expressed m7G-related genes associated with the overall survival of patients with ccRCC. To construct and validate a prognostic risk model, TCGA dataset samples were divided into training and test sets. A multiple-gene risk signature was constructed using least absolute shrinkage and selection operator Cox regression analysis, and its prognostic significance was assessed using Cox regression and survival analyses. Finally, immunohistochemistry was performed to verify the prognostic significance of this signature.Results: In total, 537 patients with ccRCC were included in this study. We found that 26 m7G RNA methylation regulators that were significantly differentially expressed. Univariate and multifactorial Cox regression analyses revealed that METTL1 expression was associated with ccRCC progression.Conclusions: METTL1 associated with m7G may serve as a potential biomarker for ccRCC prognosis and diagnosis. Moreover, it may affect the prognosis of ccRCC by regulating the tumor immune microenvironment, providing a potential therapeutic target for immunotherapy. These results provide a new perspective on the role of M7G-related RNAs in ccRCC pathogenesis.
format Article
id doaj-art-1858fd01a5e543fc8dd07de45bc6bda2
institution OA Journals
issn 1936-5233
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Translational Oncology
spelling doaj-art-1858fd01a5e543fc8dd07de45bc6bda22025-08-20T02:20:40ZengElsevierTranslational Oncology1936-52332025-01-015110220210.1016/j.tranon.2024.102202The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progressionYi Liu0Yanji Zhan1Jiao Liu2Zhengze Shen3Yudong Hu4Ling Zhong5Yuan Yu6Bin Tang7Jing Guo8Department of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China; The 3rd Affiliated Hospital, Chengdu Medical College, Chengdu Pidu District People's Hospital, Chengdu, 611730, ChinaDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, ChinaDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China; Department of Nephrology, Wushan County Peopleʼs Hospital of Chongqing, 404700, ChinaDepartment of Pharmacy, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, ChinaDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, ChinaDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, ChinaDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, ChinaDepartment of Nephrology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China; Corresponding authors.Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing University, Chongqing 400030, China; Corresponding authors.Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. 7-Methylguanosine (m7G), one of the most prevalent RNA modifications, has been reported to play an important role in ccRCC progression; however, the specific regulators of m7G modification that are involved in this function remain unclear. This study aimed to explore the correlation between regulators of m7G methylation and ccRCC progression using unsupervised machine learning methods.Methods: Transcriptome and clinical data of ccRCC were retrieved from The Cancer Genome Atlas (TCGA) database to identify differentially expressed m7G-related genes associated with the overall survival of patients with ccRCC. To construct and validate a prognostic risk model, TCGA dataset samples were divided into training and test sets. A multiple-gene risk signature was constructed using least absolute shrinkage and selection operator Cox regression analysis, and its prognostic significance was assessed using Cox regression and survival analyses. Finally, immunohistochemistry was performed to verify the prognostic significance of this signature.Results: In total, 537 patients with ccRCC were included in this study. We found that 26 m7G RNA methylation regulators that were significantly differentially expressed. Univariate and multifactorial Cox regression analyses revealed that METTL1 expression was associated with ccRCC progression.Conclusions: METTL1 associated with m7G may serve as a potential biomarker for ccRCC prognosis and diagnosis. Moreover, it may affect the prognosis of ccRCC by regulating the tumor immune microenvironment, providing a potential therapeutic target for immunotherapy. These results provide a new perspective on the role of M7G-related RNAs in ccRCC pathogenesis.http://www.sciencedirect.com/science/article/pii/S1936523324003280METTL17-methylguanosine (m7G)Clear cell renal cell carcinomaPrognosisTumor immune microenvironment
spellingShingle Yi Liu
Yanji Zhan
Jiao Liu
Zhengze Shen
Yudong Hu
Ling Zhong
Yuan Yu
Bin Tang
Jing Guo
The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression
Translational Oncology
METTL1
7-methylguanosine (m7G)
Clear cell renal cell carcinoma
Prognosis
Tumor immune microenvironment
title The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression
title_full The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression
title_fullStr The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression
title_full_unstemmed The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression
title_short The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression
title_sort 7 methylguanosine m7g methylation mettl1 acts as a potential biomarker of clear cell renal cell carcinoma progression
topic METTL1
7-methylguanosine (m7G)
Clear cell renal cell carcinoma
Prognosis
Tumor immune microenvironment
url http://www.sciencedirect.com/science/article/pii/S1936523324003280
work_keys_str_mv AT yiliu the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yanjizhan the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT jiaoliu the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT zhengzeshen the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yudonghu the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT lingzhong the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yuanyu the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT bintang the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT jingguo the7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yiliu 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yanjizhan 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT jiaoliu 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT zhengzeshen 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yudonghu 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT lingzhong 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT yuanyu 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT bintang 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression
AT jingguo 7methylguanosinem7gmethylationmettl1actsasapotentialbiomarkerofclearcellrenalcellcarcinomaprogression